Clinical trial
A Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa Associated With NR2E3 and RHO Mutations and Leber Congenital Amaurosis With Mutation(s) in CEP290 Gene
NCT05203939 is registered in ClinicalTrials.gov with Ocugen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa Associated With NR2E3 and RHO Mutations and Leber Congenital Amaurosis With Mutation(s) in CEP290 Gene
- Lead sponsor
- Ocugen
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- January 24, 2022
- Completion date
- March 31, 2027
- Enrollment
- 22 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.